1. Molecular basis of pharmacological therapy in Cushing’s disease
- Author
-
Ferone, Diego, Pivonello, Claudia, Vitale, Giovanni, Zatelli, Maria Chiara, Colao, Annamaria, Pivonello, Rosario, Albiger, ABC Group: N., Ambrogio, A., Arnaldi, G., Arvat, E., Baldelli, R., Berardelli, R., Boscaro, M., Cannavo', Salvatore, Cavagnini, F., Corsello, S. M., Cozzolino, A., De Bartolomeis, A., De Leo, M., Di Minno, G., Di Somma, C., Esposito, K., Fabbrocini, G., Foresta, C., Galderisi, M., Giordano, C., Giugliano, D., Giustina, A., Grimaldi, F., Isidori, A. M., Jannini, E., F. Lombardo, L. Manetti, Mannelli, M., Mantero, F., Marone, G., Mazziotti, G., Moretti, S., Nazzari, E., Paragliola, R. M., Pasquali, R., Pecorelli, S., Pecori Giraldi, F., Reimondo, G., Scaroni, C., Scillitani, A., Simeoli, C., Stigliano, A., Toscano, V., Trementino, L., Ferone, D, Pivonello, Claudia, Vitale, G, Zatelli, Mc, Colao, Annamaria, and Pivonello, Rosario
- Subjects
business.industry ,Endocrinology, Diabetes and Metabolism ,Humans ,Hypothalamus ,Pituitary ACTH Hypersecretion ,Pituitary Gland ,Receptors, Glucocorticoid ,Disease ,Cushing's disease ,medicine.disease ,Bioinformatics ,Clinical trial ,Endocrinology ,Pituitary adenoma ,Diabetes mellitus ,Immunology ,medicine ,Endocrine system ,business ,Receptor ,Glucocorticoid ,medicine.drug - Abstract
Cushing's disease (CD) is a severe endocrine condition caused by an adrenocorticotropin (ACTH)-pro- ducing pituitary adenoma that chronically stimulates adrenocortical cortisol production and with potentially serious complications if not or inadequately treated. Active CD may produce a fourfold increase in mortality and is associated with significant morbidities. Moreover, excess mortality risk may persist even after CD treatment. Although predictors of risk in treated CD are not fully understood, the importance of early recognition and ade- quate treatment is well established. Surgery with resection of a pituitary adenoma is still the first line therapy, being successful in about 60-70 % of patients; however, recur- rence within 2-4 years may often occur. When surgery fails, medical treatment can reduce cortisol production and ameliorate clinical manifestations while more definitive therapy becomes effective. Compounds that target hypo- thalamic-pituitary axis, glucocorticoid synthesis or adre- nocortical function are currently used to control the deleterious effects of chronic glucocorticoid excess. In this review we describe and analyze the molecular basis of the drugs targeting the disease at central level, suppressing ACTH secretion, as well as at peripheral level, acting as adrenal inhibitors, or glucocorticoid receptor antagonists. Understanding of the underlying molecular mechanisms in CD and of glucocorticoid biology should promote the development of new targeted and more successful therapies in the future. Indeed, most of the drugs discussed have been tested in limited clinical trials, but there is potential ther- apeutic benefit in compounds with better specificity for the class of receptors expressed by ACTH-secreting tumors. However, long-term follow-up with management of per- sistent comorbidities is needed even after successful treatment of CD.
- Published
- 2013
- Full Text
- View/download PDF